Mesoblast Limited (Nasdaq:MESO; ASX:MSB), a global leader in allogeneic cellular medicines for inflammatory diseases, today ...

The company signed the agreement with Karolinska Institutet's Department of Cell and Molecular Biology professor Johan ...

Crispr Therapeutics AG has revenue declines but holds strong financials. Promising Sickle Cell therapy & 2025 data readouts ...

Kytopen announces expansion of its partnership program into Europe with its agreement with T-CURX GmbH, a biotech company based in Würzburg, Germany. T-CURX, a clinically focused therapeutic company ...

Clinical trial complexity, logistical challenges associated with treatments, and resource constraints at trial sites cited as top factors that ...

No doubt 2025 will usher in many more advances in CRISPR therapies, thanks to the FDA’s new Platform Technology Designation ...

KAMPALA - Dr Matthias Magoola says the US Patent and Trademark Office (USPTO) has granted a patent for his invention of the first treatment of cancer using a novel composition of a guided Ribonucleic ...

Duchenne muscular dystrophy (DMD) is a rare hereditary disease that is associated with progressive muscle wasting. The ...

Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

PHC Corporation and CCRM have signed a Master Collaboration Agreement to collaborate on developing primary T-cell expansion ...

"We are excited to collaborat with PHC to unlock new possibilities in cell culture," explained Michael May, President and CEO ...